Sandra E. Dunn

7.7k total citations
99 papers, 5.1k citations indexed

About

Sandra E. Dunn is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Sandra E. Dunn has authored 99 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 46 papers in Oncology and 21 papers in Genetics. Recurrent topics in Sandra E. Dunn's work include RNA Research and Splicing (22 papers), Cancer Cells and Metastasis (17 papers) and Glioma Diagnosis and Treatment (16 papers). Sandra E. Dunn is often cited by papers focused on RNA Research and Splicing (22 papers), Cancer Cells and Metastasis (17 papers) and Glioma Diagnosis and Treatment (16 papers). Sandra E. Dunn collaborates with scholars based in Canada, United States and Germany. Sandra E. Dunn's co-authors include Anna L. Stratford, Kaiji Hu, J. Carl Barrett, Abbas Fotovati, Arezoo Astanehe, Jennifer Law, Cathy Lee, Jill E. Kucab, Michaël Pollak and Joel R. Leininger and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Sandra E. Dunn

97 papers receiving 5.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra E. Dunn Canada	43	3.5k	1.5k	1.1k	625	441	99	5.1k
John F. Lyons United States	32	2.7k 0.8×	1.3k 0.9×	551 0.5×	428 0.7×	475 1.1×	81	4.3k
Andrea Morrione United States	40	3.2k 0.9×	924 0.6×	866 0.8×	1.1k 1.8×	590 1.3×	92	4.7k
Gustavo Baldassarre Italy	40	3.4k 1.0×	1.6k 1.1×	1.8k 1.6×	240 0.4×	581 1.3×	134	5.1k
Paolo Michieli Italy	28	2.7k 0.8×	1.8k 1.2×	1.1k 0.9×	272 0.4×	424 1.0×	41	4.6k
Lu‐Hai Wang United States	39	3.1k 0.9×	1.4k 1.0×	1.1k 1.0×	321 0.5×	363 0.8×	87	4.6k
Oliver Stoeltzing United States	43	3.0k 0.9×	1.6k 1.0×	1.4k 1.2×	264 0.4×	299 0.7×	73	4.6k
Xianxin Hua United States	42	5.5k 1.6×	2.1k 1.4×	1.4k 1.3×	476 0.8×	868 2.0×	102	8.8k
Ryan J.O. Dowling Canada	19	3.9k 1.1×	1.6k 1.1×	1.1k 1.0×	435 0.7×	164 0.4×	29	4.8k
Bassem R. Haddad United States	33	2.4k 0.7×	1.0k 0.7×	718 0.6×	589 0.9×	229 0.5×	81	4.4k
E. Aubrey Thompson United States	42	3.3k 0.9×	1.6k 1.0×	1.2k 1.1×	179 0.3×	306 0.7×	112	5.0k

Countries citing papers authored by Sandra E. Dunn

Since Specialization

Citations

This map shows the geographic impact of Sandra E. Dunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra E. Dunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra E. Dunn more than expected).

Fields of papers citing papers by Sandra E. Dunn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra E. Dunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra E. Dunn. The network helps show where Sandra E. Dunn may publish in the future.

Co-authorship network of co-authors of Sandra E. Dunn

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra E. Dunn. A scholar is included among the top collaborators of Sandra E. Dunn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra E. Dunn. Sandra E. Dunn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barnett, Brian, Nicholas Sharp, Takeo Fujii, et al.. (2025). Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?. Cancers. 17(5). 884–884.

Kong, Tim, Angelo B. A. Laranjeira, Christopher T. Letson, et al.. (2024). RSK1 dependency in FLT3-ITD acute myeloid leukemia. Blood Cancer Journal. 14(1). 207–207. 2 indexed citations

Kosnopfel, Corinna, Heike Niessner, Tobias Sinnberg, et al.. (2023). Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion. Journal of Experimental & Clinical Cancer Research. 42(1). 175–175. 9 indexed citations

Panupinthu, Nattapon, Mihai Gagea, Yiling Lu, et al.. (2013). Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. 33(22). 2846–2856. 45 indexed citations

Fotovati, Abbas, Loic P. Deleyrolle, Cathy Lee, et al.. (2011). YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth. Cancer Research. 71(16). 5569–5578. 69 indexed citations

Davies, Alastair, Irene Barrett, Mary Rose Pambid, et al.. (2011). YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification. Oncogene. 30(34). 3649–3660. 46 indexed citations

Davies, Alastair & Sandra E. Dunn. (2011). YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention. Oncotarget. 2(5). 401–406. 14 indexed citations

Law, Jennifer, Yvonne Li, Karen To, et al.. (2010). Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability. PLoS ONE. 5(9). e12661–e12661. 43 indexed citations

To, Karen, Abbas Fotovati, Kristen M. Reipas, et al.. (2010). Y-Box Binding Protein-1 Induces the Expression of CD44 and CD49f Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance. Cancer Research. 70(7). 2840–2851. 144 indexed citations

10.

Kalra, Jessica, Brent W. Sutherland, Anna L. Stratford, et al.. (2010). Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene. 29(48). 6343–6356. 46 indexed citations

11.

Badve, Sunil, Nikail Collins, Poornima Bhat‐Nakshatri, et al.. (2010). Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers. American Journal Of Pathology. 176(5). 2139–2149. 42 indexed citations

12.

Hu, Kaiji, Cathy Lee, Dexin Qiu, et al.. (2009). Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Molecular Cancer Therapeutics. 8(11). 3024–3035. 48 indexed citations

13.

Gao, Yuanyuan, Abbas Fotovati, Cathy Lee, et al.. (2009). Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O 6-methylguanine-DNA methyltransferase. Molecular Cancer Therapeutics. 8(12). 3276–3284. 45 indexed citations

14.

Law, Jennifer, Golareh Habibi, Kaiji Hu, et al.. (2008). Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival. Cancer Research. 68(24). 10238–10246. 339 indexed citations

15.

Lee, Cathy, Yuanyuan Gao, Kaiji Hu, et al.. (2008). Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice. Cancer Research. 68(21). 8661–8666. 97 indexed citations

16.

Lee, Cathy, Michelle Wang, Yuanyuan Gao, et al.. (2008). Targeting Y-box binding protein-1 (YB-1) in Her-2 over-expressing breast cancer cells induces apoptosis via the signal transducer and activator or transcription-3 (STAT3) pathway and suppresses tumor growth.. Clinical Cancer Research. 14. 1 indexed citations

17.

Habibi, Golareh, Samuel Leung, Jennifer Law, et al.. (2008). Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research. 10(5). R86–R86. 102 indexed citations

18.

Stratford, Anna L., Golareh Habibi, Arezoo Astanehe, et al.. (2007). Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Research. 9(5). R61–R61. 122 indexed citations

19.

Wu, Joyce C., Cathy Lee, Daniel Yokom, et al.. (2006). Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2. Cancer Research. 66(9). 4872–4879. 136 indexed citations

20.

Tseng, Ping‐Hui, Yu-Chieh Wang, Jing‐Ru Weng, et al.. (2006). Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor. Molecular Pharmacology. 70(5). 1534–1541. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact